Cardiothoracic & vascular anesthesia
Postoperative Cost-effectiveness of Prophylactic Amino Acid Therapy for Renal Protection: A Modeled Economic Evaluation
Authors' conclusion
Compared with placebo, AA infusion decreases the occurrence of AKI and is cost-saving.
Study context
- Population
- Adults after cardiac surgery
- Comparison
- Intravenous amino acids vs placebo
- Outcome
- Cost per instance of acute kidney injury (AKI) averted
- Follow-up
- In-hospital
Methodological detailsdecision tree model, modeled economic evaluation, data from a recent meta-analysis, healthcare payer perspective, in-hospital time horizon, Australia, US, China, Italy and UK analysed separately
- Decision tree model
- Modeled economic evaluation
- Data from a recent meta-analysis
- Healthcare payer perspective
- In-hospital time horizon
- Australia, US, China, Italy and UK analysed separately
Pooled result
As reported in the abstract
Cost per AKI averted; expected total healthcare cost after surgery
Per patient cost saving (China)
$184
95% CI -$331 to -$32
Amino acids (AA)
Per patient cost saving (US)
$2,521
95% CI -$3,770 to -$1,260
AA
AA
$1,871 in China to $37,692 in the United States
Placebo
$2,055 in China to $40,213 in the United States
Further pooled results
| Outcome | Absolute risk reduction (95% CI) |
|---|---|
| AKI | 5.2% (5.1%–5.3%) |
Original publication
Postoperative Cost-effectiveness of Prophylactic Amino Acid Therapy for Renal Protection: A Modeled Economic Evaluation. J Cardiothorac Vasc Anesth. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →